Comparison of the VERSANT™ HCV RNA qualitative assay (transcription-mediated amplification) and the COBAS AMPLICOR™ hepatitis C virus test, version 2.0, in patients undergoing interferon-ribavirin therapy

被引：3

作者：

Germer, JJ

Zein, NN

Metwally, MA

Hoskin, TL

Harmsen, WS

Smith, TF

Patel, R ^{[1
]}

机构：

[1] Mayo Clin, Div Clin Microbiol, Rochester, MN 55905 USA

[2] Mayo Clin, Div Gastroenterol & Hepatol & Internal Med, Rochester, MN 55905 USA

[3] Mayo Clin, Sect Biostat, Rochester, MN 55905 USA

[4] Mayo Clin, Div Infect Dis, Rochester, MN 55905 USA

来源：

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2003年 / 47卷 / 04期

关键词：

D O I：

10.1016/S0732-8893(03)00149-4

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Hepatitis C virus (HCV)-infected patients were tested for the presence of HCV RNA using two qualitative assays at various time points during interferon-ribavirin therapy. Among patients treated for 48 weeks, transcription-mediated amplification and the COBAS AMPLICOR Hepatitis C Virus Test results at Week 24 predicted subsequent virologic non-response or virologic relapse in 12/15 (80%) and 8/15 (53%) patients, respectively. (C) 2003 Elsevier Inc. All rights reserved.

引用

收藏

页码：615 / 618

页数：4

相关论文

共 18 条

[1]

[Anonymous], 1999, J Hepatol, V30, P956

[2] Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT [J].

Brouwer, JT ;

Hansen, BE ;

Niesters, HGM ;

Schalm, SW .

JOURNAL OF HEPATOLOGY, 1999, 30 (02) :192-198

[3]

Comanor L, 2001, AM J GASTROENTEROL, V96, P2968, DOI 10.1111/j.1572-0241.2001.04669.x

[4] Comparative evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR version 2.0 assays for quantification of hepatitis C virus RNA in serum [J].

Germer, JJ ;

Heimgartner, PJ ;

Ilstrup, DM ;

Harmsen, WS ;

Jenkins, GD ;

Patel, R .

JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (02) :495-500

[5] Multicenter evaluation of the VERSANT HCV RNA qualitative assay for detection of hepatitis C virus RNA [J].

Hendricks, DA ;

Friesenhahn, M ;

Tanimoto, L ;

Goergen, B ;

Dodge, D ;

Comanor, L .

JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (02) :651-656

[6] Qualitative detection of hepatitis C virus RNA: Comparison of analytical sensitivity, clinical performance, and workflow of the Cobas Amplicor HCV test version 2.0 and the HCV RNA transcription-mediated amplification qualitative assay [J].

Krajden, M ;

Ziermann, R ;

Khan, A ;

Mak, A ;

Leung, K ;

Hendricks, D ;

Comanor, L .

JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (08) :2903-2907

[7] MEASUREMENT OF OBSERVER AGREEMENT FOR CATEGORICAL DATA [J].

LANDIS, JR ;

KOCH, GG .

BIOMETRICS, 1977, 33 (01) :159-174

[8] Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: Calibration to international units, enhanced genotype reactivity, and performance characteristics [J].

Lee, SC ;

Antony, A ;

Lee, N ;

Leibow, J ;

Yang, JQ ;

Soviero, S ;

Gutekunst, K ;

Rosenstraus, M .

JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (11) :4171-4179

[9]

McHutchison JG, 1999, SEMIN LIVER DIS, V19, P57

[10] Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy [J].

McHutchison, JG ;

Shad, JA ;

Gordon, SC ;

Morgan, TR ;

Ling, MH ;

Garaud, JJ ;

Albrecht, JK ;

Dienstag, JL .

JOURNAL OF VIRAL HEPATITIS, 2001, 8 (06) :414-420